Tag Archives: bmy

Bristol Q4 Beats, But Nivolumab Still Worries Market

Big pharma Bristol-Myers Squibb (BMY) beat Q4 estimates and tried to clarify the progress of its oncology program Friday, sending shares vacillating wildly on the stock market today. On Thursday, Bristol-Myers stock dropped after it posted a new nivolumab trial in lung cancer that sparked worries that this meant the ongoing trial of nivolumab in combination with Yervoy wasn’t going so well. As the market opened Friday the stock rose more than 2%,

Bristol-Myers’ New Nivolumab Trial Sparks Worries

Big pharma Bristol-Myers Squibb’s (BMY) stock was selling off nearly 3% in heavy morning trading in the stock market today. There was no news from the company, but one possible reason was that it posted a new clinical trial of nivolumab in non-small-cell lung cancer (NSCLC). The new trial studies only patients with the PD-L1 biomarker, and does not combine nivolumab with any other agents. The company is already conducting another study of the

AstraZeneca Buys Out Bristol-Myers’ Diabetes Business

British drug giant AstraZeneca (AZN) agreed to buy full ownership of the diabetes program it’s been sharing with Bristol-Myers Squibb (BMY), thus ending Bristol’s attempt at being a diabetes powerhouse. Both stocks were up on the stock market today. AstraZeneca agreed to pay $2.7 billion upfront for the assets, which include several marketed drugs such as Bydureon, Byetta and Onglyza, as well as $1.4 billion in regulatory and milestone payments